Pharmaceutical firm plans $10.4M in new equipment, 60 jobs

  • Comments
  • Print

Italy-based Sigma-Tau Pharmaceuticals Inc. plans to invest $10.4 million in new equipment at its north-side Indianapolis manufacturing facility, creating 60 jobs by 2019.

The local facility, which does business as Sigma-Tau Pharmasource Inc., currently employs 110 people. The plant is at 6925 Guion Road just south of West 71st Street and east of Interstate 465.

Sigma-Tau Pharmasource is a contract manufacturer of liquid pharmaceutical products, and it specializes in small and medium-sized production runs for rare diseases and clinical trials. The facility also makes third-party branded pharmaceutical products for its parent corporation.

The firm has landed a contract to produce a new drug for Phase 3 clinical trials, and as a result needs to increase its capacity, according to plans submitted to Indianapolis officials. The $10.4 million investment would include new mixing and refrigeration equipment, laboratory equipment, material handling equipment and IT hardware.

Sigma-Tau has requested an eight-year tax break from the city of Indianapolis on the equipment, which would save the company about $484,000 over that period.

Under the tax abatement agreement, Sigma-Tau would commit to retaining its existing 110 workers, which earn an average wage of $33.80 per hour, and add another 60 jobs at an average wage of $35.71 per hour.

The city’s Metropolitan Development Commission will consider the abatement request during its meeting on Wednesday afternoon.

During the eight-year abatement period, the company still would pay about $301,100 in personal property taxes related to the new equipment. Once the  abatement expires, Sigma-Tau would pay an estimated $81,200 annually in personal property taxes for the equipment.

City staff has recommended approval of the abatement to help offset the cost of the investment.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.